Concerns rise over AI's role in mental health therapy
Some patients have turned to A.I. to work through their challenges. Del Camp with the Ozark Center says that can be a good thing… within limits. He says that should only apply to A.I. which is designed for mental health – pointing to one app called 'Woebot'
And he adds usage should limited to milder cases for things like depression or anxiety, with more significant issues handled by human practitioners.
'It's like a brilliant child that still needs a parent there to make sure it's not saying things that are full of hubris. Not full of actual wisdom and understanding. And so, it's got some… it, it is capable of doing it, but you still need a professional at this point. For the more severe cases, you still need a professional to make sure it stays on a professional and well-grounded track,' said Del Camp, Ozark Ctr, Chief Clinical Ofc.
Camp says A.I. is also helping therapists make better use of their time, handling basic tasks like making notes from a session.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
5 hours ago
- Newsweek
Diabetes Warning Issued Over Insulin Pump Error
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A medical device manufacturer has issued an urgent correction for select insulin pumps due to a possible error that could result in insulin not being delivered, the U.S. Food and Drug Administration (FDA) announced. Tandem Diabetes Care, Inc., based in California, said the error appears as a Malfunction 16 alarm to users, and may stop insulin delivery. It can also halt communication between the insulin pump and the continuous glucose monitoring (CGM) device. Newsweek contacted Tandem Diabetes Care, Inc. for comment by email outside of regular working hours. Stock image. Tandem Diabetes Care, Inc. has issued a correction for select insulin pumps due to a possible error that could result in insulin not being delivered. Stock image. Tandem Diabetes Care, Inc. has issued a correction for select insulin pumps due to a possible error that could result in insulin not being delivered. Jens Kalaene/picture-alliance/dpa/AP Why It Matters The FDA said that if the error is not addressed it could lead to hyperglycemia - high blood sugar - in users due to insulin not being delivered. "In severe cases of hyperglycemia, the user may require hospitalization or intervention from a medical professional," it said. Hyperglycemia symptoms include extreme thirst, blurry vision, weakness, dry mouth, headaches, and frequent urination, according to the Centers for Disease Control and Prevention. What To Know The device affected by the urgent correction is the following: t:slim X2 insulin pumps. As of August 12, there had been 700 confirmed adverse events - incidents of confirmed high blood sugar or an event requiring medical intervention - and 59 reported injuries related to the device error, according to the FDA. No deaths had been reported. The FDA said that notices were sent directly to customers across the U.S. between July 22 and 24 with instructions on what to do in the event of a Malfunction 16 alarm. The company is set to release a software update to boost early detection of speaker failures, according to the FDA. The update will also introduce persistent vibration alerts to reduce potential safety risks. What People Are Saying Tandem Diabetes Care, Inc. said in its urgent medical device correction notice: "A Malfunction 16 will stop insulin delivery and terminate communication between the insulin pump and the CGM device, as well as the Tandem t:slim mobile app. If not addressed, this could result in hyperglycemia due to the malfunction resulting in the stoppage of insulin delivery and real time CGM Estimated Glucose Values (EGVs) and CGM trends. In severe cases of hyperglycemia, the user may require hospitalization or intervention from a medical professional. "Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail, or by fax." What Happens Next The company will notify affected pump users when the software update is available and request that the update is completed. Users who have concerns about their pumps can contact the company on techsupport@ or call 1-877-801-6901.
Business Wire
8 hours ago
- Business Wire
Rhythm Express Named by Inc. Magazine as One of the Fastest Growing Private Firms in America
MINNEAPOLIS--(BUSINESS WIRE)-- VivaQuant, Inc. d.b.a. Rhythm Express, a leader in remote cardiac monitoring and digital health solutions, has been recognized as one of the fastest-growing private companies in the United States by Inc. Magazine for the third consecutive year, ranking #331. VivaQuant's continued recognition reflects the company's momentum in reshaping the future of cardiac care through intelligent remote monitoring technologies. 'We are proud of the accomplishments of our team. This is a tremendous honor to make this prestigious list for the third consecutive year. It's a powerful validation of the work we're doing to make cardiac care more accessible, efficient and effective,' said Brian Brockway, CEO of VivaQuant. 'This milestone belongs to our entire team and the providers and patients who trust our solutions every day. We're proud to be driving meaningful change in patient outcomes through our Rhythm Express business and cutting-edge monitoring technologies.' 'This milestone belongs to our entire team and the providers and patients who trust our solutions every day.' — Brian Brockway, CEO Share Innovating the Future of Remote Cardiac Monitoring VivaQuant's flagship offering, Rhythm Express, delivers advanced, near-real time cardiac diagnostics via the small, one-piece, cellular enabled RX-1 mini ™ wearable device and Rhythm Access Portal™. The platform is designed to meet the growing demand for accurate, scalable and user-friendly remote cardiac monitoring services. With a continued focus on innovation and clinical excellence, VivaQuant is well-positioned to lead the next generation of digital cardiovascular care. About VivaQuant, Inc. VivaQuant, Inc. is a digital health company specializing in remote cardiac monitoring and diagnostic services. Through its Rhythm Express platform, VivaQuant combines cutting-edge wearable technology, enhanced proprietary noise removal & analytics, and clinical insight to support better outcomes for patients and providers nationwide.
Business Wire
8 hours ago
- Business Wire
Wenzel Spine Announces Limited U.S. Commercial Launch and First Cases of its Expandable panaSIa™ SI Fusion System
AUSTIN, Texas--(BUSINESS WIRE)--Wenzel Spine, Inc., a medical device company pioneering minimally invasive surgical and analytic solutions for spinal disorders, today announced completion of first cases and the U.S. limited commercial launch of its novel panaSIa™ Expandable SI Fusion System. panaSIa is the first expandable sacroiliac (SI) fusion implant cleared by the FDA and represents a major breakthrough in addressing sacroiliac joint dysfunction with enhanced biomechanical stability and procedural efficiency. Designed to be implanted using a posterior, minimally invasive technique, panaSIa provides joint fixation through controlled expansion across the ilium and sacrum, offering immediate mechanical stability while preserving surrounding tissue. The implant's integrated graft chamber allows for post-expansion bone grafting without disengaging instrumentation, facilitating optimal fusion conditions and minimizing procedural complexity. The first U.S. procedures are part of a limited commercial release taking place at select surgical centers ahead of full launch in Q4 2025. 'panaSIa is unlike any SI fusion device currently available,' said Aaron Calodney, MD, a nationally recognized leader in interventional pain medicine. 'The implant expands to eliminate micro-motion, providing immediate stabilization. By slightly distracting the joint space, it may reduce pain by removing contact between the arthritic surfaces. It's simple, elegant, and biomechanically sound—a truly next-generation solution for SI joint fusion.' The panaSIa system expands Wenzel Spine's portfolio of stand-alone expandable fusion technologies and reflects the company's long-term commitment to minimally invasive innovation and surgeon-driven design. 'This launch is a defining milestone for Wenzel Spine,' said William Wilson, CEO of Wenzel Spine. 'Our team has spent nearly two decades perfecting expandable device design, and panaSIa brings that legacy to a new clinical segment. We are proud to offer providers a differentiated, minimally invasive solution that transforms SI joint fusion with precision, control, and speed.' About panaSIa™ SI Fusion System The panaSIa SI Fusion System is a posteriorly placed, expandable implant that transfixes the ilium and sacrum to immobilize the SI joint and promote fusion. It is offered in two sizes allowing for anatomical customization, while its streamlined instrumentation enables true MIS placement. The integrated expansion mechanism and post-expansion graft delivery system simplify the workflow and reduce operative time. panaSIa is available now in limited release and will be widely available in Q4 2025. About Wenzel Spine, Inc. Headquartered in Austin, Texas, Wenzel Spine, Inc. is a privately held medical technology company committed to advancing the standard of care for spinal disorders through minimally invasive surgical innovation and data-driven solutions. Wenzel Spine's technologies are used by leading spine and pain physicians across the country to streamline surgical procedures and improve patient outcomes. To learn more, visit:
